Introduction {#Sec1}
============

The MHC is the region with the most disease associations in the human genome, but by far the greatest number and strongest associations are with autoimmune diseases. In contrast, the chicken MHC has many associations with resistance and susceptibility to infectious disease (reviewed in Kaufman [@CR17]). The chance discovery that a single classical class I and a single classical class II molecule are expressed at high levels in common chicken MHC haplotypes led us to propose the hypothesis that the BF-BL region of the chicken is a "minimal essential MHC". By this, we meant the region responsible for the major histocompatibility reactions that contains single dominantly expressed classical class I and II molecules whose properties determine the immune response (Kaufman et al. [@CR19]). At the time of this proposal, we also found that there were actually two class I genes with at least one TAP gene in between, which led us to propose that co-evolution with the antigen-presenting genes was responsible for the dominantly expressed class I gene (Kaufman et al. [@CR19]). Since that time, much evidence has been collected to support these views (Jacob et al. [@CR15]; Kaufman et al. [@CR20]; Koch et al. [@CR23]; Salomonsen et al. [@CR38]; Shaw et al. [@CR43]; Walker et al. [@CR50]; Wallny et al. [@CR51]); including the fact that many if not most non-mammalian vertebrates (as well as at least one marsupial, Belov et al. [@CR4]) have these salient features of the chicken MHC, including the strong associations of the MHC with infectious disease (Grimholt et al. [@CR10]; reviewed in Kaufman [@CR16], [@CR17], [@CR18]).

However, there is some confusion in the literature over whether the chicken MHC really is small and simple or is actually large and complicated. Many investigators, including ourselves, have characterised genes located on the chicken MHC microchromosome that in other animals are found in regions of the MHC, adjacent to the MHC, or in MHC paralogous regions (Afanassieff et al. [@CR1]; Briles et al. [@CR5]; Guillemot et al. [@CR11]; Kaufman et al. [@CR20]; Maruoka et al. [@CR26]; Miller et al. [@CR27], [@CR28], [@CR29], [@CR30]; Rogers et al. [@CR36]; Rogers and Kaufman [@CR35]; Ruby et al. [@CR37]; Salomonsen et al. [@CR38], [@CR39]; Shiina et al. [@CR44]). This has led to an alternative view that the chicken MHC is in fact very large and complex, containing many genes located in at least two separate regions, called MHC-B and MHC-Y (Afanassieff et al. [@CR1]; Delany et al. [@CR9]; Miller et al. [@CR29]; Solinhac et al. [@CR46]). We have concluded that the difference in these views lies in emphasis (Kaufman et al. [@CR21]). The minimal essential MHC concept as originally stated (Kaufman et al. [@CR19], [@CR20]) defines an MHC based on function, a region of the genome containing the classical polymorphic class I and class II genes responsible for strong histocompatibility reactions (that is, a *major histocompatibility* complex). The alternative view defines the MHC as a genomic region, with any gene ever found in or adjacent to an MHC becoming part of that MHC, and with the term itself becoming a genetic acronym rather than a functional definition. In our view, the minimal essential MHC is the selected and conserved unit of classical MHC molecules (which we call \"the classical MHC\" and which has also been dubbed \"the core MHC\", Shiina et al. [@CR44]), around which other genes come and go as part of the MHC syntenic region (which has also been referred to as \"the extended MHC\").

Whichever way one wishes to view the chicken MHC, there is no doubt that there is a small and simple region (the BF-BL region) which contains the essential polymorphic components of antigen presentation by classical MHC molecules, and that this close proximity of classical MHC genes with the polymorphic genes that process and load their peptides is a feature of many, if not most, non-mammalian vertebrates. It therefore remains interesting and important to test to what extent the single dominantly expressed MHC molecules of the chicken MHC can explain the strong genetic associations with disease resistance and vaccine responses.

We have determined simple peptide motifs for certain chicken class I molecules based on the peptides eluted from chicken class I molecules isolated from spleen and blood cells (Kaufman et al. [@CR19]; Koch et al. [@CR23]; Wallny et al. [@CR51]). There are strong MHC associations for resistance and susceptibility to the pathogens Rous sarcoma virus (RSV) and Marek's disease virus (MDV), and we found many more peptides predicted to bind class I molecules from resistant than from susceptible chicken lines. We used cell binding and assembly assays to determine which of the peptides predicted by the simple motifs would actually bind the class I molecules. For RSV, we found that vaccination with a single identified peptide would eliminate disease (Hofmann et al. [@CR12]). Since then, the utility of these motifs has been confirmed by other researchers for the pathogen avian influenza virus (Hou et al. [@CR13]; Reemers et al. [@CR34]). In this paper, we wish to examine a poultry vaccine.

Gumburo disease is caused by an immunosuppressive birnavirus called infectious bursal disease virus (IBDV) that infects and kills cells of the B lineage in chickens (reviewed in Ingrao et al. [@CR14]; Mahgoub et al. [@CR25]; Müller et al. [@CR32], [@CR33]; Schat and Skinner [@CR41]; van den Berg [@CR48]). There is biphasic age-related resistance. Chicks up to 2 weeks old frequently survive, although the bursa is ravaged, the B cell system is depleted, and thereafter birds do not respond well to vaccines. There follows a period of susceptibility, peaking at 3--4 weeks of age, during which a virulent virus will kill birds. With time, an increasing resistance to mortality develops, although the birds may still suffer immunosuppression and morbidity, evidenced by weight loss or reduction in egg-laying. The disease is controlled mainly by vaccination *in ovo*, vaccination of chicks or vaccination of laying hens, usually with an attenuated live viral vaccine and often followed by an inactivated vaccine, both of which raise antibodies mostly to the major capsid protein, viral protein 2 (VP2). However, both antigenic variation and increases in virulence of the virus have been reported, so Gumboro disease is still an economic concern for the poultry industry, and various approaches to vaccines continue to be developed.

An early experimental vaccine called fp-IBD1 was created with the VP2 as a fusion protein with β-galactosidase in a fowlpox virus vector (Bayliss et al. [@CR3]). This vaccine protects some experimental chicken lines but not others (Shaw and Davison [@CR42]). In particular, line 6~1~ (homozygous for MHC haplotype B2) and line C-B12 (homozygous for B12) were shown to be protected by fp-IBD1, while line 15I (homozygous for B15) was not. The protection in line 6~1~ was partially conferred by the fowlpox virus vector alone, while the protection in line C-B12 was not. In both cases, the protection was found not to be due to antibodies, which suggested the involvement of T cells recognising MHC molecules (Shaw and Davison [@CR42]). In this report, we extend this work to examine the contribution of the chicken MHC to protection by the vaccine fp-IBD1.

Materials and methods {#Sec2}
=====================

Animals {#d30e466}
-------

The histories of the chicken lines 6~1~ (B2), C-B4 (B4), C-B12 (B12) and 15I (B15), bred and maintained under specific pathogen-free conditions at the Institute for Animal Health (Compton, UK), have been described (Jacob et al. [@CR15]). Chicks were transferred at 1 day of age to isolation accommodation equipped with high-efficiency particle air filters. All procedures were carried out in accordance the United Kingdom Animals (Scientific Procedures) Act and were subject to local ethical review.

Backcross and mapping {#d30e477}
---------------------

F1 crosses were produced between C-B12 and 15I birds and between 6~1~ and 15I birds. Laying F1 hens were inseminated with semen from 15I birds to produce backcross progeny. Typing by microsatellite analysis (Khatib et al. [@CR22]) yielded 35 MHC heterozygous and 25 MHC homozygous progeny from the 15I x (6~1~ × 15I) backcross, and 24 MHC heterozygous and 25 MHC homozygous progeny from the 15I × (C-B12 × 15I) backcross. Together with 30 birds of each parental line, all chicks were vaccinated with fp-IBD1 and challenged with F52/70 as described below.

Fowlpox vectored vaccination {#d30e491}
----------------------------

The fowlpox virus recombinant vaccine fp-IBD1 encodes the VP2 sequence of the virulent IBVD virus F52/70 as a β-galactosidase fusion protein (Bayliss et al. [@CR3]) and was produced by tissue culture passage on chick embryo fibroblasts as previously described (Shaw and Davidson [@CR42]). Chicks were vaccinated at 1 and 3 weeks of age with 10^7^ plaque-forming units fp-IBD1 in a total volume of 50 μl. The vaccine was dropped onto a section of the wing web, and the skin punctured 30 times with a 25-gauge needle. Local inflammation was evident at the site of scarification within 2 days and resolved shortly after.

Challenge virus and infection {#d30e505}
-----------------------------

IBDV F52/70 was propagated in vivo, and the active concentration of virus was assayed to determine egg infectious dose (EID) as previously described (Butter et al. [@CR7]; Van Loon et al. [@CR49]). Chicks were challenged with 10 EID~50~ IBDV F52/70 in a total volume of 100 μl by the intranasal route, 10 days after the second vaccination with either peptide (see below) or fp-IBD1 (see above).

Peptide prediction {#d30e519}
------------------

As in Wallny et al. ([@CR51]), peptides were predicted from VP2 sequence derived from F52/70 (accession number D00869.2) by using the GCG program FINDPATTERNS (Anonymous [@CR2]) and relaxed motifs for the dominantly expressed class I molecules of two chicken haplotypes. These relaxed motifs allow both octamers and nonamers with all residues found in anchor positions by pool sequencing (Wallny et al. [@CR51]). The motifs are denoted for FINDPATTERNS by the notation xxx(x,xx)(V,I)xx(V,L,I) for B12 and xRxxxx(x,xx)Y for B15, in which x denotes any amino acid, single capital letters refer to amino acids in the IUPAC single letter code and parentheses enclose alternatives, so (x,xx) means either one or two amino acids, and (V,L,I) means either valine, leucine or isoleucine. Peptides were synthesized by fluorenylmethoxycarbonyl chemistry, purified by HPLC, and resuspended at 1 mg/ml in PBS (with up to 1 % DMSO).

Stabilisation assay {#d30e533}
-------------------

As in Wallny et al. ([@CR51]), chicken peripheral blood lymphocytes without thrombocytes were cultured (10^7^ cells per ml at 40 °C, 5 % CO2) overnight in Dulbecco's modified minimal Eagle's medium with 0.5 mg/ml bovine serum albumin (BSA) and with or without 1 mM synthetic peptides (in triplicate). Then, cells were washed (phosphate-buffered saline, 0.5 % BSA, 0.1 % NaN~3~), and flow cytometric analysis using a monoclonal antibody against chicken β~2~-microglobulin (F21-21, Skjødt et al. [@CR45]) followed by FITC-conjugated goat anti-mouse IgG (Silenus, Paris) was performed, gating on small lymphocytes.

Assembly assay {#d30e553}
--------------

As in Koch et al. ([@CR23]), inclusion bodies from β~2~m cDNA sequence (encoding the mature protein without a signal sequence but beginning with a start codon for methionine) and for BF2\*1201 cDNA (residues 1--270 of the mature protein without a signal sequence but with a codon for Met added at the beginning) in pET22b(+) were isolated from BL21 (λDE3) pLysS Rosetta cells, and dissolved in 8 M urea, 10 mM 2-mercaptoethanol, 100 mM NaH~2~PO~4~, 10 mM TrisCl, pH 8. Small-scale assembly assays were carried out at 4 °C in 1 ml refold buffer \[100 mM TrisCl pH 8.2, 400 mM arginine, 0.5 mM oxidized glutathione, 5 mM reduced glutathione, 2 mM ethylenediamine tetraacetic acid, 0.1 mM 4-(2 aminoethyl) benzenesulfonyl fluoride (Pefablock, Sigma)\]. The peptide, β~2~m and heavy chain were added slowly with vigorous stirring in a molar ratio of 10:2:1 (usually around 1:24:31 μg in 1 ml). After 18--30 h, FPLC size exclusion chromatography (AKTA, Pharmacia) with a HiLoad 26/60 Superdex 75 column (Pharmacia) in 0.15 M NaCl, 0.1 M TrisCl pH 8.2 was used to separate aggregates, monomers, heavy chains, β~2~m, peptides and smaller molecules.

Peptide vaccination {#d30e577}
-------------------

As in Hofmann et al. ([@CR12]), 18 mg L-α-phosphatidylcholine, 2 mg L-α-phosphatidyl-DL-glycerol and 5 mg cholesterol (all components from Sigma) were suspended in 5 ml chloroform and rotary evaporated under reduced pressure until a thin lipid film formed on the flask wall. Residual chloroform was removed by vacuum desiccation. Three milligrams of peptide was dissolved in 1 ml PBS containing 0.4 mg Quil A and 1 mM 2-mercaptoethanol. This solution was added to the dried lipids and slowly shaken until the lipids were re-suspended and then equilibrated 30 min at room temperature. C-B12 chicks were immunised at 1 and 3 weeks of age with 100 μg peptide in 0.2 ml of liposomes per injection, i.m. into the pectoral muscle. Some other chicks were not vaccinated, some others were vaccinated with fp-IBD1 and most chicks were challenged with F52/70 as described above. Three were ten birds per group. Blood samples were taken daily to determine viremia (Moody et al. [@CR31]). Five days post-infection, the birds were sacrificed, the bursa dissected, RNA extracted by standard techniques (Staines et al. [@CR47]) and the remaining tissue prepared for routine wax-embedded histology.

Assessment of protection {#d30e591}
------------------------

Bursal/body weight ratio, bursal damage score, peak blood viremia and bursal viral load were used as post-mortem measures of pathology. Bursal damage score is described elsewhere (Williams and Davison [@CR52]). Briefly, a histological scoring system ranging from 0, representing normal bursal architecture, to 5, representing complete loss of bursal architecture, was used to assess bursal histopathology. All slides were encoded and the scoring carried out blind, with the identity of the samples unknown. Quantitative RT-PCR was performed to determine relative amounts of VP2 gene transcripts in blood and bursal samples using the primer-probe combinations previously described (Moody et al. [@CR31]) and the results normalised against the expression of 28S RNA, determined in a duplex reaction with VP2, and presented as Log~2~R~o~ (Butter et al. [@CR8]).

Results {#Sec3}
=======

Genetic mapping shows that the chicken MHC is a major locus for response to fp-IBD1 {#Sec4}
-----------------------------------------------------------------------------------

Given that fp-IBD1 elicits very different levels of protection in different strains of chicken, we examined whether the MHC is a major genetic locus in this response. Using the high responder lines (line 6~1~ homozygous for MHC haplotype B2, C-B12 homozygous for B12) and a low responder line (15I homozygous for B15), we first bred F1 chickens (6~1~ × 15I heterozygous for B2/B15, and C-B12 × 15I heterozygous for B12/B15), then bred two backcross families, immunised with fp-IBD1, challenged with the virulent IBDV strain F52/70, and measured damage to the bursa of Fabricius.

In the first comparison (Fig. [1](#Fig1){ref-type="fig"}), the majority of the chickens of the low responder parental line 15I (B15/B15) had a high bursal damage score, while nearly all of the chickens of the high responder parental line 6~1~ (B2/B2) had little or no bursal damage. From the backcross 15I × F1 (6~1~ × 15I) family, about one quarter of the birds had a high bursal damage score, and the rest had little or no damage. After typing these chickens, we found that nearly all of the B15/B2 heterozygotes had little or no damage, but that half of the B15/B15 homozygotes had little damage and the other half had a high bursal damage score. Since genes outside of the MHC should have segregated randomly, this shows that a single B2 haplotype in a B2/B15 heterozygote chicken confers protection, which was as much as two B2 haplotypes in a B2/B2 homozygote chicken. However, there must be another gene outside of the MHC which confers responsiveness as well since half of the B15/B15 homozygote chickens were protected. Thus, there are two genetic loci that confer the responsiveness found in line 6~1~ chickens.Fig. 1Backcross mapping of protection conferred by fp-IBD1 vaccination to bursal damage by IBDV strain F52/70 challenge in two families derived from line 6~1~ (MHC haplotype B2), CB-12 (B12) and 15I (B15). The graphs represent bursal damages score, with 0 as no perceptible damage and 5 as extremely damaged (*x*-axis) against percentage birds with that score (*y*-axis). *Upper two panels* are birds from the parental lines 15I and 6~1~, and birds from the backcross family 15I × F1(15I × 6~1~) segregated into the homozygotes and heterozygotes. *Lower two panels* are birds from the parental lines 15I and C-B12, and birds from the backcross family 15I × F1(15I × C-B12) segregated into the homozygotes and heterozygotes

In the second comparison (Fig. [1](#Fig1){ref-type="fig"}), the majority of the chickens of the low responder parental line 15I (B15/B15) had a high bursal damage score, while the majority of the high responder parental line C-B12 (B12/B12) had little or no bursal damage. From the backcross 15I × F1(C-B12 × 15I) family, about half of the birds had a high bursal damage score, while half had less damage. After typing these chickens, we found that most of the B15/B15 homozygote chickens had high bursal damage score, but most of the B12/B15 heterozygote chickens had a moderate bursal damage score. Since genes outside of the MHC should have segregated randomly, this shows that a single B12 haplotype in a B12/B15 heterozygote chicken confers about half as much protection as two B12 haplotypes in a B12/B12 homozygote chicken. Thus, there is one major genetic locus that confers responsiveness found in line C-B12 chickens which is the MHC, but two copies of the C-B12 haplotype are necessary for the highest level of protection under these circumstances.

Binding and assembly assays show that the MHC-determined response to fp-IBD1 correlates with the peptides predicted to bind the MHC class I molecule {#Sec5}
----------------------------------------------------------------------------------------------------------------------------------------------------

Given that the fp-IBD1 vaccine contains IBDV VP2 protein as a fusion protein with β-galactosidase and that the mechanism of protection does not involve antibodies, it seemed most likely that the response was directed against peptides presented by class I molecules. Having determined peptide motifs for the class I molecules of the B12 and B15 haplotypes (BF2\*1201 and the BF2\*1501), we used these motifs to predict peptides from the VP2 protein sequence that might bind these class I molecules. We found 12 peptides that fit the B12 peptide motif, but only 2 peptides that fit the B15 peptide motif (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Cell binding and assembly analysis of VP2 peptides predicted to bind B12 and B15 class I molecules. *Left hand panel*, mean fluorescence intensities measuring the increase of F21-21 binding to cells after culture overnight with 1 mM peptide compared to culture overnight without added peptide. *Dotted lines* indicate the mean fluorescence intensities of the cells without incubation with peptides. Samples were analysed in triplicate, with standard errors well below 10 %. *Right hand panel*, ratio of the area of peaks corresponding to assembled monomer compared to β~2~m from size exclusion chromatography of renaturation assays with indicated peptides

From work on mammals (and our own work with these same chicken class I molecules in a previous study), generally only a fraction of peptides that fit the simple kind of motif used here actually bind the class I molecule with measurable affinity. So, we tested the binding of synthetic peptides to chicken peripheral blood lymphocytes with an assay we have used previously (Wallny et al. [@CR51]), a flow cytometry-based class I stabilisation assay analogous in procedure to the RMA-S and T2 stabilization assays using mammalian cells with defective TAP genes. As assessed by the fluorescence in comparison with no peptide controls, neither of the two B15 peptides predicted bound to B15 cells, whereas many of the predicted B12 peptides did bind (Fig. [2](#Fig2){ref-type="fig"}).

In addition, we tested the B12 peptides by an assembly assay, in which B12 heavy chain and β~2~m were renatured in the presence of peptide, and the material analysed by size exclusion chromatography, as illustrated in Fig. [3](#Fig3){ref-type="fig"}. Since the amount of β~2~m in the assay was far in excess, ratio of the areas under the peaks of monomer was taken as a measure of the success of the assembly of heavy chain and β~2~m dependent on peptide. Ten of the 12 predicted B12 peptides supported assembly very well, in agreement with the stabilisation assay (Fig. [2](#Fig2){ref-type="fig"}).Fig. 3An example of an assembly assay. Class I heavy chain was renatured with β~2~m and peptide IBDV-8, the components separated by size exclusion chromatography, and the areas under the peaks corresponding to reassembled monomer and free β~2~m (labelled and indicated by *dashed boxes*) determined

Immunisation and challenge show that a peptide from fp-IBD1 that binds the MHC class I molecule can confer resistance to IBDV {#Sec6}
-----------------------------------------------------------------------------------------------------------------------------

Having found many peptides from the vaccine fp-IBD1 that bind BF2\*1201, the dominantly expressed class I molecule from the B12 haplotype, we wanted to test whether immunisation of C-B12 chickens with one of them would protect against challenge by IBDV. We had previously developed a peptide immunisation protocol that protected against tumour progression after infection of chickens by Rous sarcoma virus. We used the same protocol of intramuscular injection of liposomes loaded with Quil A and various peptides, in comparison with no immunisation and with fp-IBD1 immunisation. Three days after challenge with IBDV strain F52/70, we measured bursal/body weight ratio, bursal damage score, peak blood viremia and bursal viral load (Figs. [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"}).Fig. 4Means of bursal/body weight ratio (×1,000; *upper panel*), bursal damage score (*second panel*), peak blood viremia (log~2~R~o~; *third panel*) and bursal viral load (log~2~R~o~; *lower panel*) in line C-B12 birds with no challenge, or after IBDV F52/70 challenge following vaccination with nothing, fp-IBD1 or different peptides. As an indication of variability means are shown with their standard errors (though the data do not conform to the strict requirements of parametric analysis)Fig. 5Percentages of line C-B12 birds with different bursal damage scores after no challenge, or after IBDV F52/70 challenge following vaccination with nothing, fp-IBD1 or different peptides

As expected, without the challenge infection, chickens had a normal bursa to body weight ratio, a low bursal damage score and no virus in the blood or bursa. All four measures rose after infection without vaccination, as well as after vaccination with two peptides, the control peptide from RSV (RSV6) and one of the peptides from fp-IBD1 (IBDV12). In contrast, protection was evident by all measures after vaccination with fp-IBD1 and even more so after vaccination with another peptide from fp-IBD1 (IBDV8). Thus, immunisation with a peptide from IBDV that binds the dominantly expressed class I molecule BF2\*1201 will protect from challenge with a virulent IBDV (Figs. [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"}).

Discussion {#Sec7}
==========

In this paper, we have shown that (1) response to a molecular defined vaccine containing the VP2 sequence of IBDV can be determined by at least two genetic loci, one of which is the MHC, (2) absence of VP2 peptides that bind the class I molecule is the basis for the lack of response in a low responder line and (3) presence of at least one VP2 peptide that binds the dominantly expressed class I molecule is the basis for the protection in a high responder line.

The work in this paper grew from earlier observations (Shaw and Davison [@CR42]) that vaccination with fp-IBD1 could protect some experimental chicken lines and not others. Examination of the mechanisms of protection showed that antibody was not involved, which is in accord with the fact that the VP2 protein as a fusion protein with β-galactosidase in the vaccine is likely to have a different three-dimensional structure compared to VP2 protein as a part of the IBDV capsid. These examinations also showed that line C-B12 was protected by vaccination with fp-IBD1 but not by the fowlpox virus vector alone, while line 6~1~ was protected somewhat even by the fowlpox virus vector alone. In contrast, line 15I was not protected.

The results in our paper fit with these previous results. From genetic mapping, line 15I is a low responder with no protective locus, C-B12 is a high responder with only one major protective locus (the MHC) and line 6~1~ is a high responder with two major protective loci (the MHC which presumably depends on the VP2 fusion protein, and another locus which may determine response to fowlpox virus vector alone, perhaps through an innate antiviral response like inflammation or natural killer cell responses). From our peptide predictions and peptide vaccination, line 15I is a low responder because the classical class I molecule BF2\*1501 does not bind peptides from the VP2 sequence, while line C-B12 is a high responder because the dominantly expressed class I molecule BF2\*1201 finds at least one VP2 peptide (IBDV-8; GNVLVGEGV) that confers protection to challenge with a virulent IBDV strain. It must be stressed that IBDV-8 may not be the only peptide that is responsible for protection, but that there is at least one such peptide. On the basis of these results, we would predict (but did not show) that line 6~1~ is a responder because the dominantly expressed class I molecule BF2\*0201 presents at least one protective IBDV peptide.

Two other interesting points emerged. First, after vaccination with fp-IBD1, the protection of B12/B15 heterozygotes in the backcross was half of that of B12/B12 homozygotes in the original line. This most likely indicates that the level of peptide bound to BF2\*1201 on the surface of cells is a critical factor in priming the immune response (as has been shown for mammals, see for example Bullock et al. [@CR6]), and that the particular conditions of vaccination are just barely sufficient to protect from the particular conditions of challenge. Second, vaccination with the VP2 peptide IBDV-12 (LAHAIGEGV) did not result in a protective immune response after vaccination, despite the fact that this peptide bound well to BF2\*1201. There are no structural differences between IBDV-8 and IBDV-12 which obviously account for this difference. The protective IBDV-8 peptide is located in the linker region between the P and S domains of VP2, while the non-protective binding CB12-IBDV-12 epitope is located deep in the S domain (Lee et al. [@CR24]) and both peptides are well conserved (indeed identical in a wide variety of IBDV sequences, including strain 52/70, accession number BAA00745; strain Cu1, BAA00740; strain STC, BAA00391; strain E/DEL, CAA38637; strain 23/82, Z21971; strain CT, CAC35470; strain UK661, CAC60256; strain 88180, CAJ34339; isolate 903/78, AFI55462; isolate SP8, AFN80509). One explanation might be that there is a hole in the T cell repertoire due to negative selection in the thymus (as has been reported in mammals, see for example Wölfl et al. [@CR53]).

The previous work (Shaw and Davison [@CR42]) used our motifs to predict the peptides for the dominantly expressed class I molecule BF2\*0401 from line C-B4 and concluded in discussion that there were no peptides that would bind, but nevertheless found that fp-IBD1 conferred the same level of protection to line C-B4 as line C-B12. One potential explanation is that another genetic locus in C-B4 is responsible for the protection, but that seems unlikely since C-B4 and C-B12 chickens are taken (as individuals or as annual sublines) from a C line flock, and so all non-MHC genes should segregate freely between the lines. Another potential explanation is that the response is due to the minor gene BF1\*0401, but this gene has virtually undetectable expression at the level of RNA, protein and antigenic peptide. Therefore, the most likely explanation for the response of C-B4 is that the previous work used a very stringent peptide motif (octamers with Asp2, Asp5 and Glu8, as we published in Kaufman et al. [@CR19]), but in fact the motif can be somewhat wider (Wallny et al. [@CR51]). The motif and even individual peptides show that Glu is also found at positions 2 and 5, and certain hydrophobic amino acids found at a low level at position 8. Moreover, some peptides may be longer, and there may be C-terminal overhangs, as we found for B12 and other haplotypes. In fact, this more relaxed motif does indeed predict 4 peptides from the VP2 in fp-IBD1.

These results are all in accord with the concept of a minimal essential MHC (Kaufman et al. [@CR19], [@CR20], [@CR21]; Kaufman [@CR17]), in which the structural organisation of the chicken MHC (compared to most mammals) has striking effects on function. We have previously shown that properties of the single dominantly expressed class I molecule can explain the responses of experimental chicken lines to RSV and MDV (Wallny et al. [@CR51]; Koch et al. [@CR23]), and the results in this paper extend this concept from viral pathogens to viral vaccines.

Moreover, IBDV continues to be a serious threat to commercial chickens, with both antigenic variation and increase in virulence reported (reviewed in Ingrao et al. [@CR14]; Mahgoub et al. [@CR25]; Müller et al. [@CR32], [@CR33]; Schat and Skinner [@CR41]; van den Berg [@CR48]). While the poultry industry generally controls IBDV through inactivated vaccines that work through class II molecules (which also show the phenomenon of MHC-determined differences in response), some attenuated viral vaccines are used, particularly in ovo (reviewed in Müller et al. [@CR33]). The likelihood that some individual chickens remain poorly protected after either form of vaccination is an unsolved problem. Given that the MHC of many, if not most, non-mammalian vertebrates have features first discovered in chickens (reviewed in Kaufman [@CR16], [@CR17]), it is likely that this is also a problem in other important contexts, for instance vaccination in some commercial fish (Grimholt et al. [@CR10]) or resistance to citrid fungi in amphibians (Savage and Zamudio [@CR40]).
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